Abbott to Present at Wells Fargo Securities Research & Economics 2013 Healthcare Conference
ABBOTT PARK, Ill., June 10, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the Wells Fargo Securities Research & Economics 2
New Four-Strain Influenza Vaccine from Sanofi Pasteur Now Licensed By FDA for Broad Age Range of Children and Adults
New Four-Strain Influenza Vaccine from Sanofi Pasteur Now Licensed By FDA for Broad Age Range of Children and Adults LYON, France, June 10, 2013 -- Sanofi Pasteur, the vaccines division of Sanofi...
GSK statement in response to FDA Advisory Committee's vote on availability of Avandia (rosiglitazone)
GSK statement in response to FDA Advisory Committee's vote on availability of Avandia (rosiglitazone) Issued: June 6, 2013, Philadelphia, PA GlaxoSmithKline [NYSE: GSK] confirmed today that a...
Actavis Confirms Generic Diprivan® Patent Challenge
Actavis Confirms Generic Diprivan® Patent Challenge
PARSIPPANY, N.J., June 7, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug...
Arena Pharmaceuticals Reports on Launch of BELVIQ® (lorcaserin HCl) CIV for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese
Arena Pharmaceuticals Reports on Launch of BELVIQ® (lorcaserin HCl) CIV for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese -- BELVIQ Available in US Pharmacies...
Amgen To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
THOUSAND OAKS, Calif., June 6, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 34<
Health Canada Expands Indications of Abilify® (aripiprazole), to be the First Add-On Treatment for Major Depressive Disorder (MDD)
MONTREAL, June 6, 2013 /CNW/ - Abilify® (aripiprazole) has received an additional approval from Health Canada
Endo Health Solutions Announces Actions To Streamline Operations And Expand Platform For Sustainable Cash Flow And Earnings Growth
MALVERN, Pa., June 5, 2013 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today outlined the strategic, operational and organizational steps it is taking to refocus the Company and drive...
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
--Gilenya improved the key measures: brain volume loss, MRI lesion...
Zydus Pioneers a Breakthrough With LIPAGLYN, India's First NCE to Reach the Market
Zydus Pioneers a Breakthrough With LIPAGLYN, India's First NCE to Reach the Market
MUMBAI, India, June 5, 2013 /CNW/ - Lipaglyn™ is the first Glitazar to be approved in the world and the...
Royalty Pharma Statement Regarding Elan Law Suits
Royalty Pharma Statement Regarding Elan Law Suits Royalty Pharma Deplores What it Believes Are Efforts by Elan to Deprive Shareholders of an Opportunity to Consider Royalty Pharma Offer Elan...
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America NORTHBROOK, Ill., June 5, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a subsidiary...
Abbott to Present at William Blair 33rd Annual Growth Stock Conference
ABBOTT PARK, Ill., June 4, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the William Blair 33rd Annual Growth S
Two Real-World European Studies of Abbott's Minimally Invasive MitraClip® Device Demonstrate Positive Outcomes for Patients with Mitral Regurgitation
- Findings Published in the Journal of the American College of Cardiology Demonstrate Significant Improvements in Day-to-Day Quality of Life
ABBOTT PARK, Ill.,
Uncovering cancer in today's anatomic pathology lab
VENTANA digital pathology software: finding and analyzing cancer with a click
TUCSON, Ariz., June 4, 2013
PRONOUNCE Study Does Not Achieve Primary Superiority Endpoint for ALIMTA® (pemetrexed for injection), Similar PFS and OS Results Were Observed Between the Two Drug and the Three Drug Regimens in the Treatment of NSCLC
CHICAGO, June 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced results from its PRONOUNCE t
AstraZeneca enters agreement with Hanmi Pharmaceuticals and Amneal Pharmaceuticals in US NEXIUM patent litigation
AstraZeneca enters agreement with Hanmi Pharmaceuticals and Amneal Pharmaceuticals in US NEXIUM patent litigation AstraZeneca today announced it has entered into an agreement with Hanmi...
PRONOUNCE Study Does Not Achieve Primary Superiority Endpoint for ALIMTA® (pemetrexed for injection), Similar PFS and OS Results Were Observed Between the Two Drug and the Three Drug Regimens in the Treatment of NSCLC
PRONOUNCE Study Does Not Achieve Primary Superiority Endpoint for ALIMTA® (pemetrexed for injection), Similar PFS and OS Results Were Observed Between the Two Drug and the Three Drug Regimens in...
